Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.53 |
| ▸ | CTSD | P07339 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | OGG1 | O15527 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18878882 | 0.85 | F2R (0.44) | F2RCTSDCA1CA2CA9 | |
| SCHEMBL31146578 | 0.85 | F2R (0.52) | F2R | |
| SCHEMBL27544568 | 0.84 | F2R (0.46) | F2RCTSDCA1CA2CA9 | |
| SCHEMBL16371787 | 0.80 | ALDH1A1 (0.50) | F2RALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL29442195 | 0.80 | ALDH1A1 (0.50) | F2RALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL14435838 | 0.80 | ALDH1A1 (0.44) | F2RALDH1A1MAPTKDM4E | |
| SCHEMBL16968451 | 0.80 | F2R (0.46) | F2RALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL2870231 | 0.80 | CTSD (0.52) | CTSDCA1CA2CA9ALDH1A1 | |
| SCHEMBL30441713 | 0.79 | F2R (0.44) | F2RALDH1A1MAPTKDM4E | |
| SCHEMBL29242369 | 0.79 | F2R (0.47) | F2RCA1CA2CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799600-B1 | Targeted nanoparticles | NANODERM SCIENCES, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190000987-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20180028684-A1 | TARGETED NANOPARTICLES | NANODERM SCIENCES, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-9694085-B2 | Targeted therapeutic nanoparticles | NANODERM SCIENCES, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| EP-2872120-B1 | THERAPEUTIC NANOPARTICLES WITH A POLYMYXIN B AS TARGETING AGENT | NANODERM SCIENCES INC (US) | 2017-05-03 | — | — | EP | disclosed |
| CN-105738612-A | Cell detection methods and reagents having a releasable labelling moiety | 美天施生物科技有限责任公司 | 2016-07-06 | — | — | CN | disclosed |
| US-20160106852-A1 | TARGETED THERAPEUTIC NANOPARTICLES | NANODERM SCIENCES, INC. (US) | 2016-04-21 | — | — | US | disclosed |
| US-9161962-B2 | Targeted therapeutic nanoparticles | NANODERM SCIENCES, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| EP-2872120-A1 | TARGETED THERAPEUTIC NANOPARTICLES | Nanoderm Sciences, Inc. (US) | 2015-05-20 | — | — | EP | disclosed |
| US-20140199232-A1 | Targeted Therapeutic Nanoparticles | NANODERM SCIENCES, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2014014890-A1 | TARGETED THERAPEUTIC NANOPARTICLES | NANODERM SCIENCES, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2012162555-A2 | HEPARIN NANOCLUSTERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-29 | — | — | WO | disclosed |
| CN-1230178-A | Polydithiocarbamate-containing macromolecules and use thereof for therapeutic and diagnostic applications | MEDINOX INC (US) | 1999-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199232-A1 | Targeted Therapeutic Nanoparticles | CD44, PHOSPHO1, CD47 | F2R 1759/4885CTSD 3225/4885CA1 870/4885 |
| US-20190000987-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | F2R 3904/4885CTSD 3982/4885CA1 3807/4885 |
| US-20160106852-A1 | TARGETED THERAPEUTIC NANOPARTICLES | CD44, PHOSPHO1, CD47 | F2R 1759/4885CTSD 3225/4885CA1 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.